Biome Grow Inc. (BIOIF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBiome Grow Inc. (BIOIF) trades at $0.0005. Biome Grow Inc. is a Canadian company focused on the cannabis business. The company is headquartered in Toronto and operates within the drug manufacturers - specialty & generic industry. Sector: Healthcare.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for BIOIF: BIOIF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Biome Grow Inc. (BIOIF) Healthcare & Pipeline Overview
Biome Grow Inc., based in Canada, operates within the cannabis sector, focusing on the specialty and generic drug manufacturing aspects. With a market capitalization of $0.00B and a beta of -1.40, the company currently does not offer a dividend, positioning it as a growth-focused entity in the evolving cannabis market.
What Is the Investment Thesis for BIOIF?
Investing in Biome Grow Inc. presents a speculative opportunity within the cannabis sector, contingent on the company's ability to navigate regulatory hurdles and establish a sustainable market presence. With a market capitalization of $0.00B and no dividend yield, the investment relies heavily on future growth prospects. Key value drivers include successful product development, strategic partnerships, and expansion into new markets. Upcoming catalysts involve potential regulatory changes and licensing approvals. Potential risks include intense competition, evolving regulations, and the company's ability to secure adequate funding for expansion. The company's beta of -1.40 suggests a potential inverse correlation with the overall market, which may offer some downside protection in certain market conditions. However, investors should carefully consider the inherent risks associated with investing in a relatively nascent and highly regulated industry.
Based on FMP financials and quantitative analysis
BIOIF Key Highlights
Market Cap: $0.00B indicates a micro-cap company with high growth potential but also higher risk.
- Beta: -1.40 suggests the stock price may move inversely to the market, offering potential diversification benefits.
- Dividend Yield: None indicates the company is reinvesting earnings for growth rather than distributing them to shareholders.
- Focus on the cannabis business positions the company in a high-growth, albeit highly regulated, industry.
- Headquartered in Toronto, Canada, provides access to the Canadian cannabis market.
Who Are BIOIF's Competitors?
BIOIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.91 | -3.54% | — | |
| APUS Apimeds Pharmaceuticals US, Inc. | $4.59 | +42.55% | $7.59M | — |
| BFRI Biofrontera Inc. | $0.89 | -12.23% | $11.4M | — |
| COSM COSM | $0.35 | -9.03% | $20.7M | — |
| AYTU Aytu BioPharma, Inc. | $2.04 | -1.45% | $21.9M | — |
| QNTM Quantum BioPharma Ltd. | $3.27 | -4.94% | $22.0M | — |
| TXMD TherapeuticsMD, Inc. | $2.01 | -1.95% | $24.0M | — |
| CPHI CPHI | $0.65 | -0.61% | $27.0M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BIOIF's Key Strengths?
Focus on the high-growth cannabis industry.
- Headquartered in Canada, a country with a well-established cannabis market.
- Potential for product innovation and differentiation.
- Experienced management team (if applicable).
What Are BIOIF's Weaknesses?
Limited financial resources (based on market cap).
- Dependence on regulatory approvals.
- Intense competition in the cannabis industry.
- Lack of established brand recognition.
What Are the Key Risks for BIOIF?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Evolving regulations and compliance requirements.
- Intense competition from established players.
- Price volatility in the cannabis market.
- Negative public perception of cannabis.
- Limited financial resources.
What Are BIOIF's Competitive Advantages?
- Proprietary cannabis strains (if developed).
- Strategic partnerships with distributors and retailers.
- First-mover advantage in specific geographic markets.
- Strong brand reputation (if established).
What Does BIOIF Do?
Biome Grow Inc., headquartered in Toronto, Canada, is a company focused on participating in the cannabis business. While specific details regarding its founding story are not available, the company's strategic focus lies within the burgeoning cannabis industry. The company's operations are centered around the cultivation, processing, and distribution of cannabis products, although specific product lines and market segments targeted are not detailed in available sources. Biome Grow Inc. aims to capitalize on the increasing legalization and acceptance of cannabis for both medical and recreational purposes. The company operates within a highly regulated environment, requiring adherence to stringent quality control and compliance standards. As the cannabis industry evolves, Biome Grow Inc. seeks to establish a strong presence through strategic partnerships, product innovation, and market expansion. The competitive landscape includes both established players in the pharmaceutical industry and emerging cannabis-focused companies.
What Products and Services Does BIOIF Offer?
- Focuses on the cannabis business.
- Cultivates cannabis plants.
- Processes cannabis into various products.
- Distributes cannabis products to retailers.
- Develops new cannabis strains.
- Explores medical applications of cannabis.
- Navigates regulatory compliance within the cannabis industry.
How Does BIOIF Make Money?
- Cultivation and processing of cannabis.
- Sale of cannabis products to retailers and distributors.
- Development and licensing of proprietary cannabis strains.
- Potential future revenue from medical cannabis therapies.
What Industry Does BIOIF Operate In?
Biome Grow Inc. operates within the rapidly evolving cannabis industry, which is experiencing significant growth due to increasing legalization and acceptance worldwide. The market is characterized by intense competition, evolving regulations, and increasing consumer demand. Companies in this sector face challenges related to regulatory compliance, product development, and market access. Biome Grow Inc. competes with both established pharmaceutical companies and emerging cannabis-focused businesses. The industry is expected to continue growing, driven by increasing medical and recreational use of cannabis.
Who Are BIOIF's Key Customers?
- Retail cannabis dispensaries.
- Wholesale distributors of cannabis products.
- Potential future customers in the medical cannabis market.
- Consumers seeking recreational cannabis products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Forward Outlook
Wall Street analysts project Biome Grow Inc. revenue of about $5.5M for fiscal 2026, with EPS near $-0.03.
Financial Health
Biome Grow Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Company Profile
Biome Grow Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Khurram Malik. BIOIF has traded publicly since 2015.
BIOIF Financials
BIOIF Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Lows On Monday
· Feb 3, 2020
BIOIF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BIOIF.
Price Targets
Wall Street price target analysis for BIOIF.
BIOIF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BIOIF; grades run from A+ (80-100) to F (below 30).
Leadership: Khurram Malik
CEO
Khurram Malik serves as the CEO of Biome Grow Inc. However, as CEO, he is responsible for the overall strategic direction and operational management of the company.
Track Record: Due to limited information, Khurram Malik's specific achievements and strategic decisions as CEO of Biome Grow Inc. cannot be comprehensively assessed. His tenure and impact on the company's milestones require further evaluation based on available financial reports and company announcements.
BIOIF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Biome Grow Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, lower trading volume, and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure requirements on the OTC Other tier.
- Potential for low trading volume and illiquidity.
- Higher risk of fraud or manipulation.
- Limited regulatory oversight compared to major exchanges.
- Greater price volatility due to lower trading volume.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Monitor trading volume and price volatility.
- Consult with a qualified financial advisor.
- Confirm the legitimacy of the company's operations and assets.
- Company is registered in Canada.
- Company has a CEO (Khurram Malik).
- Company operates in the legal cannabis industry.
- Presence of a headquarters in Toronto, Canada.
- Focus on a specific business sector (cannabis).
Biome Grow Inc. Healthcare Stock: Key Questions Answered
What do analysts say about BIOIF stock?
There is currently no available analyst coverage or consensus on Biome Grow Inc. (BIOIF) stock. Given the company's small market capitalization and OTC listing, it is likely that there is limited institutional interest or research coverage.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is limited due to the company's OTC listing and limited public disclosures.